Blog

The latest thoughts from Medicines Law & Policy partners.

UN High-Level Panel on Access to Medicines calls for stronger public leadership in innovation...

The UN High-Level Panel on Access to Medicines published its report on 14 September. The Panel was established on 19 November 2015 by UN...

Covid-19 and the comeback of compulsory licensing

The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...

Wrapping up 2019 – Noteworthy Medicines Law and Policy Events

2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....

The Power of TRIPS Flexibilities in Medicines Procurement

The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of...

It is not too late to solve the know-how problem in the WHO Pandemic...

Introduction One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...

EU Review of Pharmaceutical Incentives: Recommendations for Change

In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
INB co-chairs, Precious Matsoso from South Africa and Roland Driece from the Netherlands opening the session on 18 June

Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert...

Negotiators of a Pandemic Treaty should heed the recommendations, published 15 July in the BMJ Global Health, to design a fair global system for...

Will the European Court of Justice put a stop to the evergreening of Truvada...

Truvada, the fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a critical medicine in both HIV treatment and prevention. It is...

WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument

In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
Generic lumacaftor/ivacaftor

Cystic Fibrosis Buyers Club Shows the UK Government The Way

The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...